Keck School Faculty

Ashley Margol

Ashley Margol

Associate Professor of Clinical Pediatrics
Director of the Pediatric Neuro-Oncology Program at CHLA
Pediatrics CHLA
CHLA 4650 W. Sunset Blvd. Off Campus Los Angeles

OpenPBTA: The Open Pediatric Brain Tumor Atlas Cell Genom. 2023 Jul 12; 3(7):100340. . View in PubMed

Addendum: Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy Oncotarget. 2023 May 19; 14:502. . View in PubMed

Recent progress and novel approaches to treating atypical teratoid rhabdoid tumor Neoplasia. 2023 03; 37:100880. . View in PubMed

MR multitasking-based dynamic imaging for cerebrovascular evaluation (MT-DICE): Simultaneous quantification of permeability and leakage-insensitive perfusion by dynamic T1/T2* mapping Magn Reson Med. 2023 Jan; 89(1):161-176. . View in PubMed

Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics Neuro Oncol. 2023 01 05; 25(1):199-210. . View in PubMed

Low-pass whole-genome and targeted sequencing of cell-free DNA from cerebrospinal fluid in pediatric patients with central nervous system tumors Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad077. . View in PubMed

Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study J Clin Oncol. 2023 04 01; 41(10):1921-1932. . View in PubMed

Multi-institutional analysis of central nervous system germ cell tumors in patients with Down syndrome Pediatr Blood Cancer. 2022 10; 69(10):e29830. . View in PubMed

Novel MRI deformation-heterogeneity radiomic features are associated with molecular subgroups and overall survival in pediatric medulloblastoma: Preliminary findings from a multi-institutional study Front Oncol. 2022; 12:915143. . View in PubMed

Quantitative Nuclear Histomorphometry Predicts Molecular Subtype and Clinical Outcome in Medulloblastomas: Preliminary Findings J Pathol Inform. 2022; 13:100090. . View in PubMed

Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma Neuro Oncol. 2022 11 02; 24(11):1964-1975. . View in PubMed

Safety of Tumor Treating Fields (TTFields) therapy in pediatric patients with malignant brain tumors: Post-marketing surveillance data Front Oncol. 2022; 12:958637. . View in PubMed

Primary Primitive Neuroectodermal Tumor of the Spine With t(11;22): Report of 3 Cases and Review of Literature J Pediatr Hematol Oncol. 2021 Oct 01; 43(7):e983-e986. . View in PubMed

Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma Pediatr Blood Cancer. 2021 10; 68(10):e29172. . View in PubMed

IDH-mutant brainstem gliomas in adolescent and young adult patients: Report of three cases and review of the literature Brain Pathol. 2021 07; 31(4):e12959. . View in PubMed

Clinical utility of comprehensive genomic profiling in central nervous system tumors of children and young adults Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab037. . View in PubMed

Feasibility of Treating High Grade Gliomas in Children with Tumor-Treating Fields: A Case Series Cureus. 2020 Oct 05; 12(10):e10804. . View in PubMed

A genome-wide association study on medulloblastoma J Neurooncol. 2020 Apr; 147(2):309-315. . View in PubMed

Primary diffuse leptomeningeal glioneuronal tumors of the central nervous system: Report of three cases and review of literature Pediatr Hematol Oncol. 2020 Apr; 37(3):248-258. . View in PubMed

Central diabetes insipidus: A rare unreported side effect of temozolomide in pediatrics Pediatr Blood Cancer. 2020 12; 67(12):e28516. . View in PubMed

Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors Neuro Oncol. 2020 07 07; 22(7):944-954. . View in PubMed

SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors Neuro Oncol. 2020 06 09; 22(6):785-796. . View in PubMed

Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens J Neurooncol. 2019 Nov; 145(2):375-383. . View in PubMed

Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy Oncotarget. 2019 Jan 11; 10(4):551-557. . View in PubMed

Clinical and neuropsychological outcome of pediatric non-midline central nervous system germinoma treated with chemotherapy and reduced dose/volume irradiation: The Children's Hospital Los Angeles experience Pediatr Blood Cancer. 2019 12; 66(12):e27983. . View in PubMed

Pediatric Atypical Teratoid/Rhabdoid Tumors of the Brain: Identification of Metabolic Subgroups Using In Vivo 1H-MR Spectroscopy AJNR Am J Neuroradiol. 2019 05; 40(5):872-877. . View in PubMed

A comparative analysis of clinicopathological features and survival among early adolescents/young adults and children with low-grade glioma: a report from the Children's Oncology Group J Neurooncol. 2018 Dec; 140(3):575-582. . View in PubMed

Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors J Neurooncol. 2018 May; 138(1):199-207. . View in PubMed

Transmission of a TP53 germline mutation from unaffected male carrier associated with pediatric glioblastoma in his child and gestational choriocarcinoma in his female partner Cold Spring Harb Mol Case Stud. 2018 04; 4(2). . View in PubMed

Palliative Care Options for a Young Adult Patient with a Diffuse Intrinsic Pontine Glioma Cureus. 2017 Aug 18; 9(8):e1580. . View in PubMed

Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome Acta Neuropathol. 2017 11; 134(5):705-714. . View in PubMed

Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approach J Neurooncol. 2017 05; 133(1):119-128. . View in PubMed

Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy Pediatr Blood Cancer. 2016 09; 63(9):1527-34. . View in PubMed

Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy Neuro Oncol. 2016 Jan; 18(1):126-31. . View in PubMed

Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas Sci Transl Med. 2016 11 23; 8(366):366ra161. . View in PubMed

Tumor-associated macrophages in SHH subgroup of medulloblastomas Clin Cancer Res. 2015 Mar 15; 21(6):1457-65. . View in PubMed

Pediatric brain tumor cell lines J Cell Biochem. 2015 Feb; 116(2):218-24. . View in PubMed

Disseminated Medulloblastoma in a Child with Germline BRCA2 6174delT Mutation and without Fanconi Anemia Front Oncol. 2015; 5:191. . View in PubMed

Achieving target voriconazole concentrations more accurately in children and adolescents Antimicrob Agents Chemother. 2015; 59(6):3090-7. . View in PubMed

Pathology and diagnosis of SMARCB1-deficient tumors Cancer Genet. 2014 Sep; 207(9):358-64. . View in PubMed

PID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors and gliomas Clin Cancer Res. 2014 Feb 15; 20(4):827-36. . View in PubMed

Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells Clin Immunol. 2013 Oct; 149(1):55-64. . View in PubMed

Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers Antimicrob Agents Chemother. 2010 Nov; 54(11):4619-25. . View in PubMed

Ashley Margol, MD is originally from Jacksonville, Florida, where she and completed her undergraduate training at the University of Florida where she majored in zoology. She moved to Los Angeles to attend medical school at the Keck School of Medicine at the University of Southern California. She did her pediatric residency at Los Angeles County-University of Southern California after which she was honored to spend a fourth year as chief resident. Ashley recently completed her pediatric hematology-oncology fellowship at Children’s Hospital Los Angeles and is currently spending an additional year at Children’s Hospital Los Angeles training in pediatric neuro-oncology. Her research is examining the presence and role of inflammation in pediatric medulloblastoma, and she will complete her Masters of Science in Clinical, Biomedical and Translational Research this fall.
sc ctsi logoPowered by SC CTSI